“Pembrolizumab in Treating Patients With High-Risk Pulmonary Nodules”
This phase II trial studies how well pembrolizumab works in treating patients with high-risk pulmonary nodules. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the pre-malignant cells, and may inhibit the progression of pre-malignant cells into invasive cancer cells.
Receive standard of care
Biological - Pembrolizumab
Randomized Phase II of Immunotherapy With Pembrolizumab for the Prevention of Lung Cancer (IMPRINT-Lung)